Αρχική World News Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients With...

Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients With Lymphoid Malignancies

In heavily pretreated patients with lymphoid malignancies, zilovertamab vedotin demonstrated no unexpected side effects and showed evidence of antitumour activity in a phase I, first-in-human, dose-escalation study. The findings provide a clinical proof of concept for selective targeting of receptor tyrosine kinase-like orphan receptor 1 (ROR1), an oncofoetal protein, as a potential new therapeutic approach. The study findings are published by Prof. Michail L. Wang of the Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center in Houston, TX, US and colleagues on 12 October 2021 in The New England Journal of Medicine.

The authors wrote in the background that ROR1 is a cell-surface protein that mediates signaling from its ligand, Wnt5a, to drive physiologic embryonic stem cell proliferation. By birth, ROR1 expression disappears from almost all normal tissues. However, cancer cells that revert to a dedifferentiated state can express ROR1. ROR1-expressing haematologic and solid tumours have a high potential for self-renewal, exhibit increased survival and migration, and are associated with poor outcomes.

Zilovertamab vedotin is a novel antibody–drug conjugate comprising the humanised monoclonal antibody zilovertamab, which is highly specific for tumour tissue; a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker; and the antimicrotubule cytotoxin monomethyl auristatin E (linker-monomethyl auristatin E designated as vedotin). Zilovertamab vedotin binding to tumour cell ROR1 results in rapid internalisation, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl auristatin E release.

In mouse models of human lymphoid malignancies, zilovertamab vedotin safely induced tumour shrinkage, often causing complete regressions even with heterogenous ROR1 expression. Dose-dependent neutropenia was the only important side effect in monkeys.

In this phase I study, the authors enrolled 32 patients with previously treated (a median of 4 previous drug and/or cellular therapies) mantle cell lymphoma (n=15), chronic lymphocytic leukaemia (n=7), diffuse large B-cell lymphoma (n=5), follicular lymphoma (n=3), Richter transformation lymphoma (n=1), and marginal zone lymphoma (n=1) to receive zilovertamab vedotin every 3 weeks until the occurrence of disease progression or unacceptable toxicity had occurred.

Starting dose levels were 0.5 (n=1), 1.0 (n=3), 1.5 (n=3), 2.25 (n=11), and 2.5 (n=14) mg per kg of body weight. Pharmacokinetic and pharmacodynamic data documented systemic zilovertamab vedotin exposure and exposure-dependent zilovertamab vedotin targeting of ROR1 on circulating tumour cells.

Side effects included acute neutropenia and cumulative neuropathy resulting in a recommended zilovertamab vedotin dosing regimen of 2.5mg/kg every 3 weeks. No clinically concerning side effects occurred to suggest ROR1-mediated toxicities or non-specific zilovertamab vedotin binding to normal tissues. 

Zilovertamab vedotin induced objective tumour responses (ORRs) in 7 of 15 patients with mantle cell lymphoma (47%) with 4 partial and 3 complete responses, and in 3 of 5 patients with diffuse large B-cell lymphoma (60%) with 1 partial and 2 complete responses. The ORRs were not observed among patients with other tumour types.

The study team focused on lymphoid malignancies given their near-ubiquitous ROR1 expression and known responsiveness to non–cancer-specific, lymphocyte-targeting drugs such as brentuximab vedotin and polatuzumab vedotin that deliver monomethyl auristatin E.  The findings support further development of zilovertamab vedotin as monotherapy and combination therapy in patients with monomethyl auristatin E-sensitive haematological and solid tumours. The study data provide validation of ROR1 as a therapeutic target and support the concept that selective targeting of ROR1 may offer a novel and clinically beneficial approach, if these data can be extended in larger and longer clinical studies.

The study was sponsored by VelosBio Inc.


Wang ML, Barrientos JC, Furman RR, et al. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM; Published online 12 October 2021.  https://doi.org/10.1056/EVIDoa2100001



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...